Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents

SHANG-CHIN HUANGCheng, Pin-NanPin-NanChengCHEN-HUA LIUHUNG-CHIH YANGTUNG-HUNG SUTAI-CHUNG TSENGPEI-JER CHENJIA-HORNG KAOCHUN-JEN LIU2022-09-292022-09-292022-050929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/623260Direct-acting antiviral agents (DAAs) have revolutionized the paradigm for HCV treatment. However, patients with HBV and HCV co-infection receiving DAAs are at significant risk of HBV reactivation, with limited literature addressing the roles of serum chemokines/chemokines. We aimed to explore the profiles and predictive value of serum cytokines/chemokines regarding HBV reactivation in this clinical setting.enAcute flare; Co-infection; C–C motif chemokine ligand 2; Interferon-gamma; TNF-alpha[SDGs]SDG3Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agentsjournal article10.1016/j.jfma.2021.09.002345385522-s2.0-85114995738WOS:000798115500010